Want to join the conversation?
Jeff Holford with Jefferies asks about the ACV franchise, the ex-US sales over the next few quarters. $BMY said it has seen the maturation of its business in Japan. New competitive entrants have significantly reduced $BMY's performance there. In Europe, the company continues to sustain a very high penetration of the genotype 3 patient population.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.